Scott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $27.11, for a total transaction of $47,442.50. Following the completion of the sale, the insider now directly owns 6,781 shares in the company, valued at approximately $183,832.91. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Thursday, July 11th, Scott Bizily sold 1,996 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $49,900.00.
• On Monday, July 1st, Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $21.36, for a total value of $90,737.28.
• On Thursday, May 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $25.45, for a total value of $44,537.50.

4D Molecular Therapeutics Trading Down 4.9 %

Shares of NASDAQ:FDMT opened at $14.40 on Friday. The business has a 50-day moving average price of $23.36 and a 200 day moving average price of $24.95. The company has a market capitalization of $744.48 million, a price-to-earnings ratio of -5.90 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.07. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. As a group, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

FDMT has been the topic of a number of research reports. Barclays initiated coverage on 4D Molecular Therapeutics in a report on Monday, April 15th. They issued an “overweight” rating on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of 4D Molecular Therapeutics in a report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, June 7th. Jefferies Financial Group lifted their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of 4D Molecular Therapeutics in a report on Wednesday. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.63.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of FDMT. Wellington Management Group LLP increased its position in shares of 4D Molecular Therapeutics by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock worth $2,199,000 after purchasing an additional 3,638 shares during the last quarter. SG Americas Securities LLC grew its position in 4D Molecular Therapeutics by 119.5% in the 4th quarter. SG Americas Securities LLC now owns 26,899 shares of the company’s stock valued at $545,000 after acquiring an additional 14,645 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in 4D Molecular Therapeutics by 359.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after acquiring an additional 3,873 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in 4D Molecular Therapeutics in the 4th quarter valued at about $966,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in 4D Molecular Therapeutics by 14.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,612 shares of the company’s stock valued at $438,000 after acquiring an additional 2,700 shares in the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.